Avanzanite Bioscience Partners With Advicenne to Commercialize Sibnayal® For the Treatment of Rare Kidney Disease in Germany, Austria, Switzerland and Greece
Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a specialty pharmaceutical company offering end-to-end commercialization and distribution partnerships with research-based biopharmaceutical originators, announced today that it has signed an exclusive distribution agreement with Paris-based specialty pharmaceutical company Advicenne for a medicinal product approved by the European Commission for the treatment of distal Renal Tubular Acidosis (dRTA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005029/en/
Adam Plich, CEO & Founder (Photo: Business Wire)
Avanzanite’s Founder and CEO, Adam Plich, stated, “Today’s announcement is in lock-step with our purpose – both ethical and economic – of delivering novel medicines to patients suffering from rare diseases into markets across Europe and unlocking revenue potential for Advicenne.” Mr. Plich continued, “Since our formal corporate launch just a couple months ago, today’s announcement with Advicenne further validates our unique business model. With this partnership, we are now safely moving beyond platform validation, into a phase of execution and gaining critical mass through pipeline expansion.”
dRTA is a rare and serious kidney disease in which acid builds up in the blood. This leads to a range of symptoms including hearing loss and stunted growth in children, as well as vomiting, kidney stones and lack of alertness. The disease also causes levels of potassium in the blood to fall, which can lead to muscle weakness and paralysis.
“We too are on a mission of delivering this important new medicine to as many dRTA patients across Europe as possible,” stated Didier Laurens, Chief Executive Officer of Advicenne. “We consider that Avanzanite’s business model is tailor made for companies like Advicenne and will surely help us successfully commercialize our product in European markets where it would have taken time to build expertise with regard to pricing and reimbursement, physician engagement and distribution footprint,” Mr. Laurens concluded.
Avanzanite is advancing discussions with several other biopharmaceutical companies seeking to enter the European market to expand its portfolio breadth. Given the high number of investigational drugs in development for rare diseases, Avanzanite envisions significant opportunity to expand patient access and optimize value creation for originators. Avanzanite sees its near-term growth opportunity in late-stage or approved ultra- or other overlooked orphan medicines. Mr. Plich concluded, “We’ve cracked the code in deciphering this tricky landscape, and now, with Advicenne as a partner, in addition to our initial strategic partnership with SIFI, we are ready to take our transformational model to the next level by bringing new medicines to patients with rare diseases.”
ABOUT AVANZANITE BIOSCIENCE: Avanzanite is a commercial-stage pharmaceutical company on a mission to redefine the commercialization of orphan medicines to improve patient access across Europe and beyond. Derived from the word ‘Tanzanite’ – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian. The economic goal is to offer end-to-end commercialization and distribution partnerships to research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets; this is the unique expertise and core competency of the Avanzanite team through its decades of operating experience navigating this area. Equally important, the Company's humanitarian goal stems from its commitment to enabling access to novel medicines for patients who suffer from orphan diseases regardless of where in Europe they live. Go to www.avanzanite.com for additional information.
ABOUT ADVICENNE. Advicenne (Euronext: ALDVI) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product (ADV 7103) has received its Marketing Approval for distal renal tubular acidosis in EU and the UK. ADV 7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. For additional information see: www.advicenne.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005029/en/
Avanzanite Bioscience B.V.
+31 20 301 21 13
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Truespeed accelerates fiber network expansion with Adtran23.3.2023 16:00:00 EET | Press release
Adtran today announced that Truespeed is leveraging its fiber broadband technology to provide high-speed connectivity to more customers across the South West of England. The new network includes Adtran’s XGS-PON technology, which enables the service provider to deliver current speed tiers of up to 900Mbit/s to households and up to 10Gbit/s to its enterprise customers. The multigigabit solution empowers Truespeed to connect subscribers significantly faster while streamlining its infrastructure with fewer equipment locations in the network. “Too often, broadband providers fail to deliver services that match their marketing hype. At Truespeed, we do things differently. We’re harnessing the most advanced software-defined access innovations available to provide fiber connectivity all the way into our customers’ homes and business premises. With Adtran’s open and programmable technology, we can guarantee ultra-fast speeds and 24/7 reliability,” said James Lowther, CEO of Truespeed. “We’ve al
American Express Reveals 2023 Top Travel Trends23.3.2023 16:00:00 EET | Press release
American Express Travel® released their 2023 Global Travel Trends Report today, highlighting four global trends inspiring people to travel this year: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005091/en/ American Express Travel's 2023 Global Travel Trends Report The Rise of “Set-Jetting”: Popular movies, TV shows and social media are inspiring people to travel to places they see onscreen, like Italy, Paris, Yellowstone, and London Delicious Destinations: From top restaurants to local favorites to cooking classes, people are choosing their next destination based on what they’ll eat A Wellness Wave: Restorative vacations are on the rise as travelers prioritize self-care and mental and physical health Traveling Off the Beaten Path: Travelers want to discover hidden gems and support the local community when they visit The report, based on survey data from travelers from the United States, Australia, Canada, Mexico, Jap
FitXR expands VR Fitness offering to PICO23.3.2023 16:00:00 EET | Press release
FitXR is continuing to expand its popular virtual reality (VR) fitness offering with the UK, EU and Asia markets by launching on the popular PICO VR headsets. FitXR’s launch on PICO represents its commitment to make VR fitness accessible to all, irrespective of the user’s preference in hardware choice. As the mass market appeal in VR continues to grow, it will bring with it increased interest in hardware developers, innovation and consumer choice and in turn the desirability in multi-platform offerings like FitXR. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005314/en/ (Photo: Business Wire) In January 2023, FitXR launched two new studio offerings: Sculpt and Combat, to add to its already robust suite of offerings that include High Intensity Interval Training (HIIT), Dance and Box workout options. The launch of Sculpt (workouts inspired by barre, pilates, and isometric strength training) and Combat (workouts inspired
Altum Technologies Selected by Chevron Technology Ventures for Catalyst Program23.3.2023 16:00:00 EET | Press release
Altum Technologies, a Finnish company that has developed a patented method of cleaning technology, has been selected to participate in Chevron Technology Ventures (CTV) Catalyst Program. The deep tech company has developed a market-leading power ultrasound solution that improves process efficiency without stopping production. The collaborative program gives Altum Technologies the platform to further advance and deploy its Zero Process Downtime (ZPD) technology globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230323005027/en/ Altum Technologies has been selected to participate in Chevron Technology Ventures (CTV) Catalyst Program. The deep tech company has developed a market-leading power ultrasound solution that improves process efficiency without stopping production. (Graphic: Business Wire) Fouling and scaling are problems in most industrial processes that causeperiodic planned and unplanned shutdowns for difficult
AI/ML Capabilities Fall Short of Executive Expectations, According to a New Global Study by SoftServe23.3.2023 14:05:00 EET | Press release
New data released today by SoftServe indicates a dramatically different understanding of the value of artificial intelligence and machine learning (AI/ML) among executives at software and digital native companies. Interest in AI/ML has been heightened with the recent release of tools such as ChatGPT and the rollout of AI-powered Microsoft Bing. However, SoftServe's survey of nearly 600 IT leaders across nine countries tells a story of significant eagerness for AI/ML, but a great disappointment with it. While 56% say leadership should consider AI/ML an urgent priority to drive business results, 52% say it should be a priority to retain and appeal to skilled talent. Conversely, 72% of IT leaders say their executive team does not fully understand the technical capabilities of AI/ML and its potential for business success. Furthermore, of those surveyed, 42% say their leadership is not treating AI/ML as urgently as it should be — to the point where this vital investment is falling down the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom